ABIVAX vs Alkermes
ABIVAX (ABVX), health care, and Alkermes (ALKS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Alkermes is worth $7.6B on the stock market and ABIVAX $7.3B: Alkermes is valued at 5% more. Over the past year ABIVAX's share price has moved -26.5% and Alkermes's +59.0%.
Key facts
- ABIVAX market value
- $7.3B
- Alkermes market value
- $7.6B
- Alkermes revenue
- $1.5BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | ABIVAX | Alkermes |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.3Blower | $7.6Bhigher |
| Revenue | — | $1.5B |
| Earnings | -$372.9Mlower | $241.7Mhigher |
| Employees | 98lower | 2,050higher |
| Total assets | $648.3Mlower | $2.5Bhigher |
| Valuation | ||
| P/E | — | — |
| P/S | — | 5.2 |
| P/B | — | — |
| Dividend yield | — | — |
| Profitability | ||
| Operating margin | — | 17.2% |
| Balance sheet | ||
| Net assets | $505.1Mlower | $1.8Bhigher |
| Total liabilities | $143.3Mlower | $667.7Mhigher |
| Total debt | — | — |
| Cash on hand | $573.3Mhigher | $388.6Mlower |
| Price change | ||
| Today | -0.58%higher | -2.41%lower |
| 1 year | -26.5%lower | +59.0%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Doug Silverman0.4% / 0.3%
ABIVAX only (3)
- Peter Kolchinsky1.3%
- Andrew Spokes0.1%
- Lee Ainslie<0.1%
Alkermes only (3)
Percentages are each holding's share of that investor's reported portfolio (under "Both": ABIVAX / Alkermes). Who owns ABVX · Who owns ALKS
More on ABIVAX
Further comparisons
ABIVAX against its closest peers
Alkermes against its closest peers
Learn
Questions and answers
Which is bigger, ABIVAX or Alkermes?
By market value, Alkermes is the larger: $7.6B against $7.3B for ABIVAX.
Which superinvestors own both ABIVAX and Alkermes?
In their latest 13F filings, Doug Silverman holds both.
Cite this page
Funkfolio, “ABIVAX vs Alkermes”, data as of 17 November 2026. https://funkfolio.com/compare/abvx-vs-alks
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.